Systolic Function News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Systolic Function. Real-time updates on events, politics, business and more.

Bristol Myers Squibb to Showcase Data Across its Innovative Cardiovascular Portfolio at the European Society of Cardiology Congress 2023

August 21, 2023

New analyses, including late-breaking data and presentations on CAMZYOS® and Eliquis® , reaffirm the companys steadfast dedication to tackling cardiovascular diseases ...

United Kingdom South Korea Great Britain Roland Chen Bristol Myers Squibb Maksabedian Hernandez

Source: marketscreener.com

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)

April 26, 2023

If approved, CAMZYOS would be the first cardiac myosin inhibitor in Europe that specifically targets the source of obstructive HCM Recommendation based on positive Phase 3 EXPLORER-HCM and... | June 18, 2023

Roland Chen Bristol Myers Squibb York Heart Association Committee For Medicinal Products Human Use European Commission Exchange Commission

Source: marketscreener.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Systolic Function News Today

Bristol Myers Squibb to Showcase Data Across its Innovative Cardiovascular Portfolio at the European Society of Cardiology Congress 2023

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS&#xAE; (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)

Explore More Categories

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)